Cargando…

The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer

BACKGROUND: Protein tyrosine kinase (PTK) signaling pathway has been confirmed to be involved in the proliferation, differentiation and migration of tumor cells. Anlotinib, as a multi-target tyrosine kinase inhibitor, which can inhibit the expression of vascular endothelial growth factor receptor (V...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Wubin, Sun, Guoqiang, Li, Zhitao, Wu, Fan, Sun, Guangshun, Cao, Hongyong, Zhou, Jin, Ma, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Surgery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039330/ https://www.ncbi.nlm.nih.gov/pubmed/35495754 http://dx.doi.org/10.3389/fsurg.2022.895982

Ejemplares similares

Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma
por: Sun, Guoqiang, et al.
Publicado: (2022)

Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway
por: Guangshun, Sun, et al.
Publicado: (2022)

Emerging Mechanisms and Treatment Progress on Liver Metastasis of Colorectal Cancer
por: Zheng, Wubin, et al.
Publicado: (2021)

Treatment of patients with cancer using PD-1/PD-L1 antibodies: Adverse effects and management strategies (Review)
por: Sun, Guangshun, et al.
Publicado: (2022)

circCORO1C promotes the proliferation and metastasis of hepatocellular carcinoma by enhancing the expression of PD‐L1 through NF‐κB pathway
por: Wu, Fan, et al.
Publicado: (2021)

Single-cell RNA sequencing in cancer: Applications, advances, and emerging challenges
por: Sun, Guangshun, et al.
Publicado: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
por: Li, Zhitao, et al.
Publicado: (2021)

Application of Animal Models in Cancer Research: Recent Progress and Future Prospects
por: Li, Zhitao, et al.
Publicado: (2021)

Combination of Anti-PD-1 Antibody, Anlotinib and Pegaspargase “Sandwich” With Radiotherapy in Localized Natural Killer/T Cell Lymphoma
por: Sun, Peng, et al.
Publicado: (2022)

Comprehensive Analysis of VCAN Expression Profiles and Prognostic Values in HCC
por: Sun, Guangshun, et al.
Publicado: (2022)

WNT5a in Colorectal Cancer: Research Progress and Challenges
por: Sun, Guangshun, et al.
Publicado: (2021)

Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer
por: Yuan, Meng, et al.
Publicado: (2022)

Clinical efficacy of PD-1 inhibitor combined with radiotherapy in a multi-drug resistant patient with liver metastasis from gastric cancer
por: Xu, Judi, et al.
Publicado: (2023)

Circ-SFMBT2 promotes the proliferation of gastric cancer cells through sponging miR-182-5p to enhance CREB1 expression
por: Sun, Handong, et al.
Publicado: (2018)

Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
por: Sun, Guoqiang, et al.
Publicado: (2021)

GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
por: Rong, Dawei, et al.
Publicado: (2023)

Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
por: Yuan, Min, et al.
Publicado: (2021)

Efficacy and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Epithelial Ovarian Cancer: A Retrospective Study
por: Li, Xiao-Yuan, et al.
Publicado: (2022)

A Retrospective Study of Anlotinib Combined with Anti-PD-1 Inhibitors in the 2nd or Later-Line Treatment of Advanced Solid Tumors
por: Li, Shu-hui, et al.
Publicado: (2023)

Effective low-dose Anlotinib induces long-term tumor vascular normalization and improves anti-PD-1 therapy
por: Fan, Peng, et al.
Publicado: (2022)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
por: Yuan, Min, et al.
Publicado: (2022)

MFAP2 Promotes the Proliferation of Cancer Cells and Is Associated With a Poor Prognosis in Hepatocellular Carcinoma
por: Zhu, Xiang, et al.
Publicado: (2020)

Over-Expression of GUSB Leads to Primary Resistance of Anti-PD1 Therapy in Hepatocellular Carcinoma
por: Kong, Xiangyi, et al.
Publicado: (2022)

Risk factors for distant metastasis and prognosis in stage T1 esophageal cancer: A population-based study
por: Zhu, Kai, et al.
Publicado: (2023)

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma
por: Wang, Hai-ying, et al.
Publicado: (2020)

Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report
por: Mao, Jiwei, et al.
Publicado: (2023)

Efficacy and Safety of Anlotinib Combined with Liposomal Doxorubicin Followed by Anlotinib Maintenance in Metastatic Soft Tissue Sarcomas
por: Liu, Zhiyong, et al.
Publicado: (2021)

Gastric infiltration of hepatic sarcomatoid carcinoma: A case report and literature review
por: Ma, Shuoshuo, et al.
Publicado: (2023)

Efficacy and Safety of Camrelizumab in Combination with Docetaxel + S-1 Sequenced by Camrelizumab + S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial
por: Dong, Zhongyi, et al.
Publicado: (2022)

Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer: A Mega Meta-Analysis
por: Baral, Shantanu, et al.
Publicado: (2022)

Study on Influencing Factors Analysis of Gastric Tube Insertion Length and Construction of Estimation Method
por: Zhang, Hua, et al.
Publicado: (2022)

Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma
por: Sun, Xin, et al.
Publicado: (2022)

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study
por: Du, Xin-Xing, et al.
Publicado: (2022)

Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report
por: Sun, Li, et al.
Publicado: (2020)

Clinical Activity and Safety of Anlotinib Combined with PD-1 Blockades for Patients with Previously Treated Small Cell Lung Cancer
por: Hao, Yan-Yan, et al.
Publicado: (2021)

Efficacy and safety of anlotinib combined with PD‐1/PD‐L1 inhibitors as second‐line and subsequent therapy in advanced small‐cell lung cancer
por: Yu, Lian, et al.
Publicado: (2022)

Comparison of Four Lymph Node Staging Systems in Gastric Adenocarcinoma after Neoadjuvant Therapy – A Population-Based Study
por: Lai, Hongkun, et al.
Publicado: (2022)

Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy
por: Sun, Guangshun, et al.
Publicado: (2022)

Case Report: Anlotinib Combined With Sintilimab as Third-Line Treatment in a Metastatic Urothelial Bladder Carcinoma Patient With FGFR3 Mutation
por: Cao, Jian-zhou, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aedap8i29mf6alhq67ts1mk48k